Monoamine transporter availability in Parkinson's disease patients with or without depression

被引:69
|
作者
Hesse, Swen [1 ]
Meyer, Philipp M. [1 ]
Strecker, Karl [2 ]
Barthel, Henryk [1 ]
Wegner, Florian [2 ]
Oehlwein, Christian [3 ]
Isaias, Ioannis Ugo [2 ]
Schwarz, Johannes [2 ]
Sabri, Osama [1 ]
机构
[1] Univ Leipzig, Dept Nucl Med, D-04103 Leipzig, Germany
[2] Univ Leipzig, Dept Neurol, D-04103 Leipzig, Germany
[3] Specialized Parkinsons Dis Outpatient Ctr, Gera, Germany
关键词
SPECT; Dopamine; Serotonin; Striatum; Midbrain; POSITRON-EMISSION-TOMOGRAPHY; SEROTONIN TRANSPORTERS; STRIATAL DOPAMINE; NEUROPSYCHIATRIC SYMPTOMS; I-123-FP-CIT SPECT; LIMBIC SYSTEM; BETA-CIT; BINDING; IMPAIRMENT; BRAIN;
D O I
10.1007/s00259-008-0979-7
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Depression is a common symptom in patients suffering from Parkinson's disease (PD) and markedly reduces their quality of life. As post-mortem studies have shown, its presence may reflect extensive cell loss in the midbrain and brainstem with imbalances in monoaminergic neurotransmitters. However, in vivo evidence of specific monoaminergic deficits in depressed PD patients is still sparse. Therefore, we studied PD patients with depression (PD+D) and without depression (PD-D) using high-resolution single-photon emission computed tomography (SPECT) and the monoamine transporter marker [I-123]FP-CIT. A magnetic resonance imaging-based region-of-interest analysis was applied to quantify the specific-to-nondisplaceable [I-123]FP-CIT binding coefficient V(3)aEuro(3) in the striatum, thalamus and midbrain/brainstem regions. PD+D patients had significantly lower V(3)aEuro(3) compared with PD-D patients in the striatum (p < 0.001), thalamus (p=0.002), and midbrain/brainstem (p=0.025). Only PD+D patients without selective serotonin reuptake inhibitor (SSRI) treatment showed lower thalamic and midbrain V(3)aEuro(3) than controls (p < 0.001, p=0.029). In a small sub-group of SSRI-treated PD+D patients neither thalamic V(3)aEuro(3) nor midbrain/brainstem V(3)aEuro(3) differed from those in PD-D patients (p=0.168, p=0.201) or controls (p=0.384, p=0.318). Our data indicate that depression in PD is associated with a more pronounced loss of striatal dopamine transporter availability that is most likely secondary to increased dopaminergic degeneration. In addition, depressed PD patients have a lower availability of midbrain/brainstem monoamine transporters than nondepressed PD patients. These findings provide in vivo evidence in support of the known post-mortem data demonstrating more extensive nerve cell loss in PD with depression and indicate that SPECT imaging can help to identify pathophysiological changes underlying nonmotor symptoms in this common movement disorder.
引用
收藏
页码:428 / 435
页数:8
相关论文
共 50 条
  • [31] Distribution characteristics of vesicular monoamine transporter in brain of mice with Parkinson disease
    Tian, Xiang-Yang
    Li, Shu-Yan
    Sun, Xing-Zhen
    Chen, Lin-Fang
    Sun, Bo
    Ni, Gui-Hua
    Zhao, Wei-Dong
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2016, 9 (08): : 8380 - 8385
  • [32] Oxidative Stress and Aminopeptidases in Parkinson's Disease Patients with and without Treatment
    Duran, Raquel
    Barrero, Francisco J.
    Morales, Blas
    Luna, Juan D.
    Ramirez, Manuel
    Vives, Francisco
    NEURODEGENERATIVE DISEASES, 2011, 8 (03) : 109 - 116
  • [33] Current coffee consumption is associated with decreased striatal dopamine transporter availability in Parkinson's disease patients and healthy controls
    Wang, Chao
    Zhou, Cheng
    Guo, Tao
    Jiaerken, Yeerfan
    Yang, Siyu
    Xu, Xiaopei
    Hu, Ling
    Huang, Peiyu
    Xu, Xiaojun
    Zhang, Minming
    BMC MEDICINE, 2023, 21 (01)
  • [34] Depression Is Associated With Constipation in Patients With Parkinson's Disease
    Qin Xiao-ling
    Chen Gang
    Lu Bo
    Li Zai-li
    Liu Xue-kui
    Li Xue
    Shi Ming-yu
    Du Yin-zhen
    Chen Xu
    Gao Dian-shuai
    FRONTIERS IN NEUROLOGY, 2020, 11
  • [35] Current coffee consumption is associated with decreased striatal dopamine transporter availability in Parkinson’s disease patients and healthy controls
    Chao Wang
    Cheng Zhou
    Tao Guo
    Yeerfan Jiaerken
    Siyu Yang
    Xiaopei Xu
    Ling Hu
    Peiyu Huang
    Xiaojun Xu
    Minming Zhang
    BMC Medicine, 21
  • [36] Monoamine Reuptake Inhibitors in Parkinson's Disease
    Huot, Philippe
    Fox, Susan H.
    Brotchie, Jonathan M.
    PARKINSONS DISEASE, 2015, 2015
  • [37] Apathy in patients with Parkinson disease without dementia or depression A PET study
    Robert, Gabriel
    Le Jeune, Florence
    Lozachmeur, Clement
    Drapier, Sophie
    Dondaine, Thibault
    Peron, Julie
    Travers, David
    Sauleau, Paul
    Millet, Bruno
    Verin, Marc
    Drapier, Dominique
    NEUROLOGY, 2012, 79 (11) : 1155 - 1160
  • [38] Distributional characteristics of vesicular monoamine transporter 2 in human embryonic brain and their correlation with Parkinson's disease
    Tian, Xiangyang
    Sun, Zhujuan
    Ding, Xinsheng
    Min, Min
    Sun, Xingzhen
    AFRICAN JOURNAL OF PHARMACY AND PHARMACOLOGY, 2012, 6 (34): : 2531 - 2535
  • [39] Increased dopamine transporter density in Parkinson's disease patients with social anxiety disorder
    Moriyama, Tais S.
    Felicio, Andre C.
    Chagas, Marcos H. N.
    Tardelli, Vitor S.
    Ferraz, Henrique Ballaiai
    Tumas, Vitor
    Amaro-Junior, Edson
    Andrade, Luiz Augusto F.
    Crippa, Jose Alexandre
    Bressan, Rodrigo A.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2011, 310 (1-2) : 53 - 57
  • [40] Neuroimaging of depression in Parkinson's disease: a review
    Chagas, Marcos Hortes N.
    Linares, Ila M. P.
    Garcia, Giovana Jorge
    Hallak, Jaime E. C.
    Tumas, Vitor
    Crippa, Jose Alexandre S.
    INTERNATIONAL PSYCHOGERIATRICS, 2013, 25 (12) : 1953 - 1961